ToxSci Advance Access originally published online on June 8, 2007
Toxicological Sciences 2007 99(1):315-325; doi:10.1093/toxsci/kfm154
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mouse Liver Effects of Cyproconazole, a Triazole Fungicide: Role of the Constitutive Androstane Receptor
* Syngenta Crop Protection, Inc., Greensboro, North Carolina 27419
Syngenta Central Toxicology Laboratory, Alderley Park, Cheshire, United Kingdom
Syngenta Crop Protection AG, Basel, Switzerland
Department of Environmental Sciences and Engineering, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599
1 To whom correspondence should be addressed at Syngenta Crop Protection, Inc., P.O. Box 18300, 410 Swing Road, Greensboro, NC 27419-8300. Fax: (336) 632-7581. E-mail: richard.peffer{at}syngenta.com.
Received March 16, 2007; accepted May 30, 2007
 |
Abstract |
|---|
Cyproconazole, a triazole fungicide, causes hepatocellular adenomas and carcinomas in CD-1 mice at dose levels of 100 and 200 ppm. The constitutive androstane receptor (CAR) has been shown to play a significant role in the overall mode of action for several nongenotoxic rodent carcinogens such as phenobarbital. The liver effects of dietary cyproconazole or phenobarbital were investigated after 2, 7, or 14 days in male CD-1, C57BL/6J, and C3H/HeNClrBR mice. Cyproconazole produced similar, dose-responsive effects in all three strains of mice, and the response was similar to that of phenobarbital. Subsequently, Car-null and wild-type male mice on a C3H/HeNClrBR background were administered 200 or 450 ppm cyproconazole, or 850 ppm phenobarbital for up to 7 days. In wild-type mice, 200 ppm cyproconazole caused liver hypertrophy, increased liver weight and cell proliferation, single-cell necrosis and fat vacuolation, effects generally similar to those caused by 850 ppm phenobarbital. Plasma cholesterol was decreased by both compounds, but cyproconazole had a greater effect. The higher dose (450 ppm) of cyproconazole caused similar changes, but greater evidence of liver damage was observed, including a large increase in plasma transaminases. Induction of CAR target genes Cyp2b10 and Gadd45ß was observed with both compounds, whereas the cell cycle regulatory gene Mdm2 was unaffected. In Car-null mice, the effects noted with either cyproconazole or phenobarbital were absent or greatly diminished. These experiments demonstrate that short-term liver effects of cyproconazole in mice are CAR-dependent and similar to those of phenobarbital, a known nongenotoxic rodent liver carcinogen.
Key Words: cyproconazole; triazole; constitutive androstane receptor; Mdm2; Gadd45ß; liver.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. K. Goetz and D. J. Dix Mode of Action for Reproductive and Hepatic Toxicity Inferred from a Genomic Study of Triazole Antifungals Toxicol. Sci., August 1, 2009; 110(2): 449 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nesnow, W. Ward, T. Moore, H. Ren, and S. D. Hester Discrimination of Tumorigenic Triazole Conazoles from Phenobarbital by Transcriptional Analyses of Mouse Liver Gene Expression Toxicol. Sci., July 1, 2009; 110(1): 68 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Phillips, L. D. Burgoon, and J. I. Goodman Phenobarbital Elicits Unique, Early Changes in the Expression of Hepatic Genes that Affect Critical Pathways in Tumor-Prone B6C3F1 Mice Toxicol. Sci., June 1, 2009; 109(2): 193 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Ross, T. Moore, and S. A. Leavitt In vivo mutagenicity of conazole fungicides correlates with tumorigenicity Mutagenesis, March 1, 2009; 24(2): 149 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Giantin, M. Carletti, F. Capolongo, S. Pegolo, R. M. Lopparelli, F. Gusson, C. Nebbia, M. Cantiello, P. Martin, T. Pineau, et al. Effect of Breed upon Cytochromes P450 and Phase II Enzyme Expression in Cattle Liver Drug Metab. Dispos., May 1, 2008; 36(5): 885 - 893. [Abstract] [Full Text] [PDF]
|
|